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The number of pediatric inflammatory bowel disease (IBD) 
patients receiving long-term Immuno-suppressive therapy (IS) 
has increased in the past several years. The administration 
of live attenuated vaccines (LAV) should be avoided in these 
patients.1 Our needs assessment survey examined current 
vaccination practices and related knowledge of primary care 
physicians regarding vaccination of IBD patients receiving IS 
therapy.
Method:
Online close-ended, 13-item questionnaires were sent to 
primary care physicians including residents and attendings from 
pediatrics and family practice at the local institution.  Descriptive 
statistics are reported and comparisons of responses between 
pediatric and family medicine providers were made using chi-
square.  
Results:




residents (30%, N=18) and 
practicing physicians (70%, 
N=42) and encompassed 
both pediatric (43%, N=26) 
and family medicine (57%, 
N=34) specialties.
Conclusion:
There is significant misconception among primary care 
physicians regarding safe vaccination practices for pediatric 
patients receiving IS therapy. More education is necessary for 
pediatric and family medicine providers to improve physician 
knowledge and ensure safe immunization administration for 
pediatric IBD patients receiving long-term Immuno-suppressive 
therapy.
Table 1.  Vaccination Pediatric IBD patient receiving IS therapy
 Recommended Considered Safe
Intranasal Flu 5% 18%
Varicella 12% 17%
MMR 17% 32%
Naser Tolaymat MD, FACG; Clare M. Lenhart, PhD, MPH
•		83% of responders reported having patients on IS. 
•		Most respondents (53%, N=32) have treated pediatric patients on IS 
therapy;
•		Thirty-nine percent of responders (N=23) review vaccination history 
at every visit. 
•		Nearly all providers identified non-live attenuated vaccines as 
safe (94%-100% depending on vaccine type) and recommend 
administration to IS patients.
•		However, survey responses identified challenges in provider 
knowledge and perception of safety surrounding life attenuated 
vaccines. 
•		Providers have recommended live attenuated vaccines to IS 
pediatric patients. Intranasal Flu 5% (N=3), varicella 12% (N=7) and 
MMR 17% (N=10).
•		Intranasal influenza was considered a safe vaccine by 18% of 
respondents (N=11), varicella by 17% (N=10) and MMR by 32% 
(N=19). 
•		A greater proportion of family medicine physicians considered 
varicella and MMR vaccines safe to  administer to IS patients than 
did pediatricians (varicella, 24% versus 8%, p=0.2; MMR, 41% 
versus 19%, P=0.126). 
Table 2.  Vaccines considered safe in Pediatric IBD patient receiving IS therapy
 Family Physicians Pediatricians P-value
Varicella 24% 8% 0.2
MMR 41% 19% 0.126
•		Further, fewer family medicine providers (35%, N=12) than 
pediatricians (69%, N=18) correctly identified all three live attenuated 
vaccines as unsafe to administer to IS patients (p=0.019). 
Desired Sources of Additional Information on Vaccine Safety
Source Percent N
Printed document in the office 61.70% 37
Flyer on office wall 16.70% 10
Grand Rounds presentation 21.70% 13
Intranet reference 56.70% 34
Reference within EMR/powerchart 18.30% 11
AAP’s Red Book 11.70% 7
Other 6.70% 4
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